The world's only, China's first! Thyda's 4th new immunotherapy drug is on the market!

Today, Cynda Biopharmaceutical Group announced that its anti-tumor drug Dabohua ®, developed jointly with Lilly Pharmaceutical Group of the United States, has been officially approved by the State Drug Administration for the treatment of diffuse large B-cell lymphoma fleatic lymphoma and chronic lymphocytic leukemia®®® The four approved monoclonal antibody drug Cynda Bio has thus become China's largest number of single anti-drug market pharmaceutical companies and the only pharmaceutical company in the history of the world founded 9 years, that is, there are 4 single-anti-product listed pharmaceutical companies Litoxi single-resistant Dabohua malignant lymphoma is the most common blood system malignancy, is China's morbidity and mortality rate of one of the top ten malignant tumors, in recent years, the incidence rate is on the rise.
diffuse large B-cell lymphoma, fyratic lymphoma, and chronic lymphocytic leukemia, all belong to B-cell non-Hodgkin's lymphoma.
expression of CD20 on the surface of tumor cells is a common feature of these diseases.
Dabohua® is a single-clone antibody targeted at CD20, such as guided missiles, precisely binding to CD20 molecules, on the one hand, activate immune cells, so that immune cells produce cytotoxic effect, resulting in tumor cell disintegration and destruction, and ultimately kill tumor cells;
launch of the Dabohua ®, jointly developed by Cynda Bio and Lilly, will provide high-quality and affordable lysoxi monoantigen injections to more Chinese patients.
As a special result of the country's major new drug creation Dabohua® the listing will effectively reduce the cost of drug use of related patients to improve clinical drug access to better meet the needs of the people for high-quality biological drugs Xinda Biomedical Science and Strategic Oncology Vice President Dr. Zhou Hui said, "Xinda Bio is currently China has the largest number of single-anti-listed pharmaceutical companies, but also the world's only 9 years since the establishment of four single-resistant products listed pharmaceutical companies."
we will continue to adhere to the original intention of developing high-quality biological drugs that people can afford, and to develop more innovative drugs that benefit more patients in China and around the world.
"About Theda Biology" began with letter, reached the line", the development of people can afford high-quality biological drugs, is the ideal and goal of Xinda biology.
founded in 2011, Essida Bio is committed to the development, production and marketing of innovative drugs for the treatment of major diseases such as cancer, metabolic diseases and autoimmunity.
31, 2018, Thyda Biopharmaceuticals was listed on the Main Board of the Stock Exchange of Hong Kong Limited under stock code 01801.
has worked hard in the biopharmaceutical industry for many years and achieved remarkable results in December 2018, with Lilly co-developing the Dabershu ® listed for the treatment of relapsed/refractic classic Hodgkin's lymphoma, and in 2019 became the only PD-1 single resistance to enter the national health insurance directory.
(click to see) In August, Thyme Bio and Lilly signed an agreement to expand global strategic cooperation on Dabershu ®, granting Lilly Daboshu® exclusive commercialization rights outside China, the first time that Chinese companies have made innovative drugs worldwide, benefiting people around the world.
in June, vegemically developed by Cinda Bio, the anti-VEGF monoantigen ®, was approved for the treatment of non-small cell lung and colorectal cancer, in addition to licensing the commercial interests of ® to the U.S. pharmaceutical company Coherus.
(click to see) In early September this year, Cynda Bio independently developed the first non-tumor product anti-TNF-α dent anti-Sulysin® was approved for the market, for the treatment of strong spina bifida, rheumatoid arthritis, psoriasis.
the fourth product approved, Dabohua ® is the second single-anti-drug drug to be developed by Xinhua Bio and Lilly Pharmaceuticals in partnership, after Dabershu ®.
(click to view) the current Suzhou Industrial Park to create the best industrial ecology, innovative ecology for the development of the biopharmaceutical industry to create the best environment Xinda bio as a beacon of significance of the benchmark enterprises rooted in the park, Yongcheng Daye in the field of biopharmaceutical industry bright results let us firmly confident that in this innovative land to continue to produce a miracle for the benefit of mankind: Jiang Yun Editing: Qing Qing Picture: Park Media Center Xinda Bio.